Copyright: ©Author(s) 2026.
World J Diabetes. Jun 15, 2026; 17(6): 119913
Published online Jun 15, 2026. doi: 10.4239/wjd.119913
Published online Jun 15, 2026. doi: 10.4239/wjd.119913
Table 1 Demographic and baseline clinical features in type 2 diabetes mellitus patients with or without proteinuria progression, mean ± SD/n (%)
| Variables | Total T2DM | T2DM with proteinuria progression (n = 390) | T2DM without proteinuria progression (n = 1063) | t/χ2 value | P value |
| Age (year) | 17.4 | < 0.01 | |||
| < 45 | 357 (24.6) | 76 (19.5) | 281 (26.4) | ||
| 45-55 | 341 (23.5) | 78 (20.0) | 263 (24.8) | ||
| 46-65 | 373 (25.7) | 109 (27.9) | 264 (24.8) | ||
| > 65 | 382 (26.3) | 127 (32.6) | 255 (24.0) | ||
| Sex | 17.03 | < 0.01 | |||
| Male | 933 (64.2) | 217 (55.6) | 716 (67.3) | ||
| Female | 520 (35.8) | 173 (44.4) | 347 (32.7) | ||
| Course of T2DM (month), median (IQR) | 79 (50-161) | 95.5 (60.0-190.0) | 73.0 (46.0-140.0) | 34.51 | < 0.01 |
| BMI (kg/m2), median (IQR) | 25.5 (23.3-27.8) | 25.8 (23.7-28.3) | 25.4 (23.1-27.6) | 6.27 | 0.02 |
| WC | 91.8 ± 9.3 | 92.8 ± 9.4 | 91.5 ± 9.2 | 2.42 | 0.02 |
| SBP, median (IQR) | 127.0 (118.0-139.0) | 130 (120-140) | 126 (117-138) | 8.94 | < 0.01 |
| DBP, median (IQR) | 77.0 (70.0-84.0) | 77 (70-84) | 77 (70-84) | 0.1 | 0.76 |
| Smoking | 489 (33.7) | 114 (29.2) | 375 (35.3) | 4.67 | 0.03 |
| Drinking | 483 (33.2) | 103 (26.4) | 380 (35.8) | 11.21 | < 0.01 |
| Family history of DM | 704 (48.5) | 169 (43.3) | 535 (50.3) | 5.59 | 0.02 |
| Medical history | |||||
| Hypertension | 593 (40.8) | 206 (52.8) | 387 (36.4) | 31.8 | < 0.01 |
| Hyperlipidemia | 442 (30.4) | 129 (33.1) | 313 (29.4) | 1.78 | 0.18 |
| Hyperuricemia | 136 (9.4) | 38 (9.7) | 98 (9.2) | 0.09 | 0.76 |
| Coronary heart diseases | 77 (5.3) | 17 (4.4) | 60 (5.6) | 0.94 | 0.33 |
| Stroke | 27 (1.9) | 14 (3.6) | 13 (1.2) | 8.76 | < 0.01 |
| Heart failure | 2 (0.1) | 0 (0.0) | 2 (0.2) | 0.73 | 0.39 |
| Metabolic indicators | |||||
| FBG, median (IQR) | 7.6 (6.4-9.6) | 7.7 (6.4-9.3) | 7.7 (6.4-9.7) | 0.34 | 0.56 |
| F-INS, median (IQR) | 57.9 (38.5-91.0) | 54.6 (38.5-85.0) | 58.5 (38.5-93.7) | 0.9 | 0.35 |
| F-CP, median (IQR) | 546.0 (381.3-748.0) | 553 (396-751) | 543 (381-745) | 0.33 | 0.56 |
| HbA1c (%), median (IQR) | 8.1 (6.8-9.9) | 8.1 (6.8-9.9) | 8.1 (6.8-10.0) | 0.35 | 0.56 |
| GA (%), median (IQR) | 19.5 (16.0-25.2) | 19.5 (15.6-24.9) | 19.5 (16.2-25.4) | 0.9 | 0.34 |
| TC (mmol/L), median (IQR) | 4.9 (4.1-5.7) | 4.7 (3.9-5.6) | 4.9 (4.1-5.7) | 8.14 | < 0.01 |
| TG (mmol/L), median (IQR) | 1.6 (1.1-2.4) | 1.7 (1.2-2.5) | 1.6 (1.2-2.4) | 0.88 | 0.34 |
| LDL-C (mmol/L), median (IQR) | 2.8 (2.2-3.5) | 2.7 (2.1-3.4) | 2.9 (2.2-3.6) | 5.45 | 0.02 |
| HDL-C (mmol/L), median (IQR) | 1.1 (0.9-1.2) | 1.0 (0.8-1.2) | 1.0 (0.9-1.2) | 2.99 | 0.08 |
| Cr (μmol/L), median (IQR) | 60.2 (49.9-70.8) | 57.4 (49.3-70.2) | 60.9 (51.2-71.5) | 6.11 | < 0.01 |
| UA (μmol/L), median (IQR) | 331.1 (273.0-396.0) | 326.0 (273.8-396.4) | 331.9 (272.8-395.5) | 0.03 | 0.88 |
| hsCRP (mg/L), median (IQR) | 1.3 (0.6-3.0) | 1.4 (0.7-3.2) | 1.2 (0.6-2.9) | 6.08 | < 0.05 |
| UACR, median (IQR) | 15.1 (7.6-37.1) | 23.9 (13.9-48.3) | 12.2 (6.4-31.8) | 80.68 | < 0.01 |
| Proteinuria-related medication | |||||
| RAS blocker | 389 (26.8) | 98 (25.1) | 291 (27.4) | 0.73 | 0.39 |
| GLP-1RA | 312 (21.5) | 110 (28.2) | 202 (19.0) | 14.32 | < 0.01 |
| SGLT-2I | 557 (38.3) | 157 (40.3) | 400 (37.6) | 0.83 | 0.36 |
Table 2 Mean and standard deviation of the 12 metabolic indexes among type 2 diabetes mellitus patients with and without the proteinuria progression during follow-up, mean ± SD
| Variables | T2DM with proteinuria progression (n = 390) | T2DM without proteinuria progression (n = 1063) | t/Z value | P value |
| BMI (kg/m2) | 25.68 ± 3.39 | 25.09 ± 3.25 | 2.85 | 0.04 |
| BMI (kg/m2), median (IQR) | 0.87 (0.61-1.17) | 0.77 (0.56-1.10) | 2.55 | 0.01 |
| SBP (mmHg) | 133.16 ± 12.78 | 128.44 ± 12.45 | 5.96 | < 0.01 |
| SBP (mmHg), median (IQR) | 11.55 (8.91-14.87) | 10.50 (7.86-13.45) | 3.78 | < 0.01 |
| DBP (mmHg) | 76.32 ± 8.34 | 75.83 ± 8.07 | 0.97 | 0.33 |
| DBP (mmHg), median (IQR) | 6.43 (4.95-8.49) | 6.12 (4.62-8.13) | 2.27 | 0.02 |
| FBG (mmol/L) | 7.65 ± 2.97 | 7.15 ± 1.39 | 4.30 | < 0.01 |
| FBG (mmol/L), median (IQR) | 3.77 (3.25-4.37) | 3.61 (3.18-4.22) | 2.64 | < 0.01 |
| HbA1c (%) | 7.25 ± 1.13 | 7.02 ± 1.02 | 3.59 | < 0.01 |
| HbA1c (%), median (IQR) | 0.88 (0.48-1.49) | 0.87 (0.46-1.67) | 0.58 | 0.56 |
| GA (%) | 17.44 ± 4.09 | 16.90 ± 3.58 | 2.44 | 0.02 |
| GA (%), median (IQR) | 2.73 (1.62-4.64) | 2.67 (1.43-4.93) | 0.25 | 0.80 |
| TC (mmol/L) | 4.57 ± 0.98 | 4.57 ± 0.86 | 0.01 | 0.99 |
| TC (mmol/L), median (IQR) | 0.71 (0.46-1.02) | 0.70 (0.44-0.99) | 1.00 | 0.32 |
| TG (mmol/L) | 2.00 ± 2.16 | 1.80 ± 1.41 | 2.07 | 0.04 |
| TG (mmol/L), median (IQR) | 0.44 (0.26-0.79) | 0.43 (0.24-0.71) | 1.06 | 0.29 |
| LDL-C (mmol/L) | 2.53 ± 0.69 | 2.58 ± 0.70 | 1.20 | 0.23 |
| LDL-C (mmol/L), median (IQR) | 0.55 (0.34-0.83) | 0.55 (0.34-0.79) | 0.94 | 0.35 |
| HDL-C (mmol/L) | 1.09 ± 0.28 | 1.10 ± 0.26 | 0.98 | 0.33 |
| HDL-C (mmol/L), median (IQR) | 0.12 (0.09-0.17) | 0.12 (0.81-0.17) | 0.59 | 0.55 |
| Cr (μmol/L) | 65.93 ± 25.57 | 67.13 ± 28.93 | 0.72 | 0.47 |
| Cr (μmol/L), median (IQR) | 6.01 (3.97-8.71) | 5.39 (3.72-7.41) | 2.75 | < 0.01 |
| UA (μmol/L) | 335.44 ± 73.05 | 334.64 ± 73.85 | 0.18 | 0.86 |
| UA (μmol/L), median (IQR) | 46.55 (34.14-67.92) | 43.66 (30.76-63.77) | 2.43 | 0.02 |
- Citation: Ma YH, Wei XH, Liu Y, Gu LP, Shen TT, Fan TT, Qin Q, Zhang AF, Wang RP, Wang YF. Visit-to-visit variability of creatinine levels associated with proteinuria progression in Chinese patients with type 2 diabetes mellitus. World J Diabetes 2026; 17(6): 119913
- URL: https://www.wjgnet.com/1948-9358/full/v17/i6/119913.htm
- DOI: https://dx.doi.org/10.4239/wjd.119913